EICHORPublic-registry site landscape for NCT02638805, “Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide”, a Diabetes Mellitus, Type 2 study sponsored by Intarcia Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02638805 (registry record) |
| Study title | Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide |
| Official title | An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide |
| Sponsor | Intarcia Therapeutics |
| Condition(s) | Diabetes Mellitus, Type 2 |
| Phase | PHASE3 |
| Listed sites | 36 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02638805.
Eichor generates a preliminary site-risk snapshot for NCT02638805 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetes Mellitus, Type 2 trials
More from Intarcia Therapeutics
← Eichor home · All tracked trials · Diabetes Mellitus, Type 2 studies · Weekly briefs
